Creative Medical Technology Holdings (CELZ) Interest Coverage Ratio (2010 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Interest Coverage Ratio of 23840.76 for Q2 2023, up 207.09% quarter-over-quarter from 22261.4 in Q1 2023.
Creative Medical Technology Holdings (CELZ) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Interest Coverage Ratio for 14 consecutive years, with 23840.76 the latest figure, recorded in Q2 2023.
- In Q2 2023, Interest Coverage Ratio changed N/A year-over-year to 23840.76; the TTM figure through Mar 2024 stood at 112604.18 (up 9983.26% YoY), while the FY2025 annual figure was 0.67, up 11.29% from the prior year.
- Interest Coverage Ratio climbed to 23840.76 in Q2 2023 per CELZ's latest filing, from 22261.4 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 23840.76 in Q2 2023 and bottomed at 22261.4 in Q1 2023.
- Historically, Interest Coverage Ratio has averaged 103.73 across 5 years, with a median of 0.64 in 2021.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio jumped 17497.32% — and 2023, when it slumped 17607.05%.
- Creative Medical Technology Holdings' Interest Coverage Ratio stood at 0.18 in 2019, then sank by 377.07% to 0.84 in 2020, then advanced by 26.89% to 0.61 in 2021, then jumped by 18223.37% to 111.08 in 2022, then soared by 21361.83% to 23840.76 in 2023.
- Business Quant data shows CELZ's Interest Coverage Ratio at 23840.76 in Q2 2023, 22261.4 in Q1 2023, and 111.08 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 2.82 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.08 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.42 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 76.86 |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -284.03 |
| Jun 30, 2023 | 23,840.76 |
| Mar 31, 2023 | -22,261.40 |
| Sep 30, 2022 | 111.08 |
| Mar 31, 2022 | -125.72 |
| Dec 31, 2021 | -0.61 |
| Sep 30, 2021 | -0.64 |
| Jun 30, 2021 | -2.20 |
| Mar 31, 2021 | -0.90 |
| Sep 30, 2020 | -0.84 |
| Jun 30, 2020 | -0.72 |
| Mar 31, 2020 | -1.04 |
| Dec 31, 2019 | -0.18 |
| Sep 30, 2019 | -0.52 |
| Jun 30, 2019 | -0.55 |
| Mar 31, 2019 | -0.55 |
| Sep 30, 2018 | -0.73 |
| Jun 30, 2018 | -0.76 |
| Mar 31, 2018 | -1.07 |
| Dec 31, 2017 | -1.35 |